ELAN
Elanco Animal Health, Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$24.68
−2.47%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$25.13
From 52W high−8.05%
Volume1.34M
Market cap$12.33B
P/E (TTM)—
P/S (TTM)2.5x
Div yield—
Key dataNov 5, 2026
Open
$25.13
From 52W high
−8.05%
Volume
1.34M
Market cap
$12.33B
ValuationView details →
P/E (Fwd)
20.4x
EV/EBITDA
20.3x
P/E (TTM)
—
RSI (14)
70.0
MomentumView details →
1D Return
−2.47%
YTD Return
+11.11%
SummaryUpdated Jun 1, 2026
Elanco Animal Health Incorporated (NYSE:ELAN) is a leading global animal health company that develops, manufactures, and markets products for both companion animals (pets) and farm animals. Founded in 1954 as a division of Eli Lilly and Company, Elanco operated as part of the pharmaceutical giant for over six decades before being spun off as an independent public company in September 2018. The company is headquartered in Greenfield, Indiana, and has established itself as one of the largest animal health companies worldwide, serving veterinarians, pet owners, and livestock producers across more than 90 countries.
Similar companies
Latest newsMore news →
Elanco Animal Health appointed Jamie Preston as executive vice president and chief people officer, effective November 3, 2026; Dave Kinard intends to retire at year-end and will support the transition.14d agoPurdue University and Elanco Animal Health Inc broke ground on a planned 150,000-square-foot One Health Research Institute in Indianapolis.21d ago